Droloxifene

Research use only, not for human use.

A nonsteroidal selective estrogen receptor modulator (SERM) that shows 10- to 60-fold increased affinity for the estrogen receptor compared with Tamoxifen.

A nonsteroidal selective estrogen receptor modulator (SERM) that shows 10- to 60-fold increased affinity for the estrogen receptor compared with Tamoxifen; has reduced partial estrogen agonistic activity.Breast Cancer Phase 2 Clinical.

Droloxifene (10 nM; 16-18 hours) induces apoptosis in MCF-7 cells. Cell Viability Assay Cell Line:MCF-7 cells Concentration:10 nM Incubation Time:16-18 hours Result:Induced cells apoptosis

Droloxifene (5-20 mg/kg; p.o.; daily for 4 weeks) increases BMD of DFM at 10mg/kg, and completely prevents the decrease of BMC and BMD of DFM induced by ovariectomized (OVX) at 20 mg/kg/day. Animal Model:5-month-old sham-operate ratsDosage:5, 10, 20 mg/kg Administration:Oral; daily for 4 weeks Result:BMD of DFM increased significantly at 10mg/kg; completely prevented the decrease of BMC and BMD of DFM induced by OVX at 20 mg/kg/day.

3-Hydroxytamoxifen | FK-435

Endocrinology/Hormones

Estrogen Receptor/ERR

Estrogen Receptor/ERR

Cancer

Breast Cancer

82413-20-5

387.52

C26H29NO2

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (129.03 mM)

CCC(=C(C1=CC=C(C=C1)OCCN(C)C)C2=CC(=CC=C2)O)C3=CC=CC=C3

(Z)-4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol

(-20℃)

With Ice Pack

≥ 2 years